Alavi Karim, Schwartz Marshall Z, Prasad Rajeev, O'connor Darlise, Funanage Vicky
Department of Surgery and Musculoskeletal Inherited Disease Laboratories at the Alfred I. DuPont Hospital for Children, Wilmington, DE, USA.
J Pediatr Surg. 2002 Mar;37(3):327-30. doi: 10.1053/jpsu.2002.30805.
This study was designed to evaluate the potential growth factor effects of systemic administration of leptin on mucosal mass and absorptive function in normal rat intestine.
Twenty male Sprague-Dawley rats underwent placement of a jugular venous catheter connected to a subcutaneous osmotic pump designed to deliver its contents at a constant rate. The rats were divided into 4 groups (n = 5 per group) based on the contents of the osmotic pump: group 1, 0.1% bovine serum albumin; group 2, leptin, 6.25 microgram/kg/d; Group 3, leptin, 18.75 microgram/kg/d; Group 4, leptin, 43.75 microgram/kg/d. After a 14-day infusion, [(14)C] galactose and [(14)C] glycine absorption were determined using a closed, recirculation technique. DNA content was determined from mucosal biopsies. Total RNA was extracted from mucosal samples, reverse transcribed, and amplified via polymerase chain reaction for the following primer pairs: sodium/glucose cotransporter (SGLT-1), fructose transporter (GLUT-5), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, internal standard). Statistical analysis was performed by analysis of variance and expressed as mean plus minus SEM.
Systemic administration of increasing doses of leptin enhanced DNA content when compared with the appropriate control (group 2, 1.06 plus minus 0.04 [P <.05]; group 3, 1.1 plus minus 0.05 [P <.01]; and group 4, 1.07 plus minus 0.06 [P <.05]. Leptin enhanced mucosal absorptive function (galactose: group 2, 2.31 plus minus 0.15 [P <.01]; group 3, 2.71 plus minus 0.06 [P <.01]; group 4, 2.19 plus minus 0.28 [P <.05]; glycine: group 2, 2.34 plus minus 0.31 [P <.05]; group 3, 3.32 plus minus 0.14 [P <.01]; group 4, 3.1 plus minus 0.27 [P <.01]) in the normal intestine when compared with the appropriate control animals. Also, leptin enhanced the gene expression of the carbohydrate transporters when compared with the appropriate control rats.
These data show that systemic leptin administration enhances mucosal mass and absorptive function in normal rat intestine. Thus, leptin appears to be a growth factor for normal small intestine and may play a role in patients who acquire intestinal dysfunction.
本研究旨在评估全身给予瘦素对正常大鼠肠道黏膜质量和吸收功能的潜在生长因子效应。
20只雄性Sprague-Dawley大鼠接受颈静脉导管植入,导管连接至皮下渗透泵,该渗透泵设计为以恒定速率输送其内容物。根据渗透泵的内容物将大鼠分为4组(每组n = 5):第1组,0.1%牛血清白蛋白;第2组,瘦素,6.25微克/千克/天;第3组,瘦素,18.75微克/千克/天;第4组,瘦素,43.75微克/千克/天。输注14天后,采用封闭循环技术测定[¹⁴C]半乳糖和[¹⁴C]甘氨酸的吸收。从黏膜活检中测定DNA含量。从黏膜样本中提取总RNA,反转录,并通过聚合酶链反应对以下引物对进行扩增:钠/葡萄糖共转运蛋白(SGLT-1)、果糖转运蛋白(GLUT-5)和甘油醛-3-磷酸脱氢酶(GAPDH,内标)。采用方差分析进行统计分析,并以均值±标准误表示。
与相应对照组相比,全身给予递增剂量的瘦素可提高DNA含量(第2组,1.06±0.04 [P <.05];第3组,1.1±0.05 [P <.01];第4组,1.07±0.06 [P <.05])。与相应对照动物相比,瘦素增强了正常肠道的黏膜吸收功能(半乳糖:第2组,2.31±0.15 [P <.01];第3组,2.71±0.06 [P <.01];第4组,2.19±0.28 [P <.05];甘氨酸:第2组,2.34±0.31 [P <.05];第3组,3.32±0.14 [P <.01];第4组,3.1±0.27 [P <.01])。此外,与相应对照大鼠相比,瘦素增强了碳水化合物转运蛋白的基因表达。
这些数据表明,全身给予瘦素可增强正常大鼠肠道的黏膜质量和吸收功能。因此,瘦素似乎是正常小肠的生长因子,可能在患有肠道功能障碍的患者中发挥作用。